S
5.25
-0.07 (-1.32%)
| Previous Close | 5.32 |
| Open | 5.32 |
| Volume | 2,224,830 |
| Avg. Volume (3M) | 1,679,225 |
| Market Cap | 1,068,206,144 |
| Price / Book | 5.02 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -0.490 |
| Total Debt/Equity (MRQ) | 20.08% |
| Current Ratio (MRQ) | 14.91 |
| Operating Cash Flow (TTM) | -95.63 M |
| Levered Free Cash Flow (TTM) | -56.02 M |
| Return on Assets (TTM) | -38.97% |
| Return on Equity (TTM) | -75.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Savara, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.40 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.38% |
| % Held by Institutions | 98.53% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Savara Announces Participation in Upcoming Investor Healthcare Conferences |
| 27 Jan 2026 | Announcement | Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* |
| 16 Jan 2026 | Announcement | Savara Announces New Employment Inducement Grant |
| 08 Jan 2026 | Announcement | PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |